An editor has performed a search and found that
sufficient sources exist to establish the subject's
notability. (January 2023) |
![]() | |
Clinical data | |
---|---|
Trade names | Promycin [1] |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
KEGG | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C16H20N4O5 |
Molar mass | 348.359 g·mol−1 |
3D model ( JSmol) | |
| |
|
Porfiromycin is an N-methyl derivative of the antineoplastic antibiotic, mitomycin C, which is isolated from various Streptomyces bacterial species. [2] As an antineoplastic agent, it is under investigation for the treatment of cancer, particularly head and neck cancer. [1]
Porfiromycin works by generating oxygen radicals and alkylating DNA, resulting in interstrand cross-links and single-strand breaks. This inhibits DNA synthesis and leads to the death of cancer cells. It has a higher toxicity towards hypoxic cells, making it an attractive option for cancer treatment. [2]
Porfiromycin can increase the risk of methemoglobinemia when taken with certain medications. [1] It belongs to the class of compounds known as mitomycins, which are characterized by their aziridine ring linked to a 7-amino-6-methyl-cyclohexa[b]pyrrolizine-5,8-dione structure. [1]
An editor has performed a search and found that
sufficient sources exist to establish the subject's
notability. (January 2023) |
![]() | |
Clinical data | |
---|---|
Trade names | Promycin [1] |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
KEGG | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C16H20N4O5 |
Molar mass | 348.359 g·mol−1 |
3D model ( JSmol) | |
| |
|
Porfiromycin is an N-methyl derivative of the antineoplastic antibiotic, mitomycin C, which is isolated from various Streptomyces bacterial species. [2] As an antineoplastic agent, it is under investigation for the treatment of cancer, particularly head and neck cancer. [1]
Porfiromycin works by generating oxygen radicals and alkylating DNA, resulting in interstrand cross-links and single-strand breaks. This inhibits DNA synthesis and leads to the death of cancer cells. It has a higher toxicity towards hypoxic cells, making it an attractive option for cancer treatment. [2]
Porfiromycin can increase the risk of methemoglobinemia when taken with certain medications. [1] It belongs to the class of compounds known as mitomycins, which are characterized by their aziridine ring linked to a 7-amino-6-methyl-cyclohexa[b]pyrrolizine-5,8-dione structure. [1]